Common Side Effects of GLP-1 Agonists: What You Need to Know

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 agonists can cause side effects like nausea, vomiting, and diarrhea, with rare risks of pancreatitis and hypoglycemia. Monitor symptoms and consult a doctor if severe.

# Side Effects of GLP-1 Agonists: What You Need to Know

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications widely used in the management of type 2 diabetes mellitus (T2DM) and increasingly in obesity treatment. These drugs mimic the action of the endogenous incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety.

While GLP-1 agonists offer significant benefits, including glycemic control and weight loss, they also come with potential side effects that patients and healthcare providers should recognize and manage. This article explores the common and less common adverse effects of GLP-1 agonists, provides dosing protocols, and highlights considerations for safe use.

---

Overview of GLP-1 Agonists

Commonly Used GLP-1 Agonists

  • Exenatide (Byetta, Bydureon)
  • Liraglutide (Victoza, Saxenda)
  • Dulaglutide (Trulicity)
  • Semaglutide (Ozempic, Wegovy)
  • Lixisenatide (Adlyxin)

    • These agents differ in structure, dosing frequency, and specific indications but share a similar mechanism of action.

    Typical Dosing Protocols

  • Exenatide: 5 mcg subcutaneously twice daily, can increase to 10 mcg twice daily.
  • Liraglutide: Starting 0.6 mg daily subcutaneously, titrated weekly to 1.2 to 1.8 mg daily for diabetes; up to 3 mg daily for weight management.
  • Dulaglutide: 0.75 mg once weekly, up to 1.5 mg weekly.
  • Semaglutide: Starting at 0.25 mg once weekly, increased every 4 weeks to 1.0 mg once weekly; higher doses (up to 2.4 mg weekly) for obesity.
  • Lixisenatide: 10 mcg daily for 14 days, then 20 mcg daily.

    • Note: Dose titration is important to improve tolerability.

    ---

    Common Side Effects of GLP-1 Agonists

    1. Gastrointestinal Symptoms

    The most frequently reported side effects involve the gastrointestinal (GI) tract due to slowed gastric emptying and central effects on appetite:

  • Nausea: Occurs in 20-30% of patients, usually mild-to-moderate, most common early in treatment.
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal discomfort or pain

    • Management Tips:

  • Gradual dose escalation can reduce severity.
  • Taking medications with food may help.
  • Hydration is essential.
  • Anti-emetics may be used in severe cases under supervision.

    • 2. Hypoglycemia

    GLP-1 agonists alone have a low risk of hypoglycemia because they enhance glucose-dependent insulin secretion. However, risk increases when combined with insulin or sulfonylureas.

    Recommendations:

  • Monitor blood glucose regularly.
  • Consider lowering doses of insulin or sulfonylurea when initiating GLP-1 agonists.

    • 3. Injection Site Reactions

  • Redness, itching, or swelling at the injection site may occur.
  • Usually mild and transient.
  • Rotating injection sites can reduce risk.

    • ---

    Less Common but Serious Side Effects

    1. Pancreatitis

    Cases of acute pancreatitis have been reported in patients using GLP-1 agonists. Although causality is not definitively established, the FDA recommends vigilance.

    Clinical Signs to Watch For:

  • Severe persistent abdominal pain
  • Nausea/vomiting
  • Elevated pancreatic enzymes

    • Action:

  • Discontinue GLP-1 agonist if pancreatitis is suspected.
  • Seek immediate medical evaluation.

    • 2. Thyroid C-cell Tumors (in Animal Studies)

    Rodent studies have shown an increased incidence of medullary thyroid carcinoma (MTC) with some GLP-1 agonists. While this has not been confirmed in humans, agents like liraglutide carry a boxed warning.

    Contraindications:

  • Personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Regular monitoring is advised in patients on long-term therapy.

    • 3. Acute Kidney Injury

    Rare cases have been reported, often secondary to severe nausea, vomiting, or dehydration leading to volume depletion.

    Preventive Measures:

  • Maintain adequate hydration.
  • Monitor renal function periodically.
  • Adjust dosing in patients with impaired renal function.

    • 4. Gallbladder Disease

    Some evidence suggests an increased risk of cholelithiasis (gallstones) and cholecystitis, possibly related to weight loss-induced bile stasis.

    ---

    Other Considerations

    Antibody Formation

    Some patients may develop antibodies to exenatide or other GLP-1 agonists, which might reduce efficacy or cause allergic reactions.

    Cardiovascular Effects

    GLP-1 agonists may have cardioprotective effects, reducing major adverse cardiovascular events in high-risk populations, but monitoring for side effects remains essential.

    ---

    Practical Protocol for Initiating GLP-1 Agonists

  • Patient Assessment:

    • - Review medical history for pancreatitis, thyroid disease, renal impairment.

    - Educate patient about potential side effects and signs to watch.

  • Start With Low Dose:

    • - Follow specific agent titration schedules.

    - Example: start liraglutide at 0.6 mg daily for one week, then increase.

  • Monitor and Follow-Up:

    • - Assess tolerance and side effects after 1-2 weeks.

    - Monitor blood glucose and renal function as appropriate.

    - Adjust dose or discontinue based on side effect severity.

  • Lifestyle Counseling:

    • - Emphasize hydration and diet to minimize GI symptoms.

    - Discuss injection technique.

  • Emergency Plan:

    • - Advise immediate medical attention for abdominal pain or signs of allergic reactions.

    ---

    Conclusion

    GLP-1 agonists are effective agents for managing type 2 diabetes and obesity, offering benefits beyond glucose lowering, such as weight loss and cardiovascular risk reduction. However, they are associated with a spectrum of side effects, predominantly gastrointestinal, that can affect patient adherence and quality of life.

    While most side effects are mild and manageable, serious adverse events like pancreatitis or thyroid tumors, though rare, necessitate careful patient selection, monitoring, and prompt intervention when suspected.

    Always consult your healthcare provider before starting or stopping GLP-1 agonist therapy to ensure it is safe and appropriate for your condition. Proper titration, monitoring, and patient education are key to maximizing benefits and minimizing risks.

    ---

    References

  • Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
  • Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–1844.
  • FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and thyroid cancer with GLP-1 drugs. FDA.gov.
  • Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21.

    • ---

    This content is for informational purposes only and does not substitute professional medical advice. Always talk to your healthcare provider regarding any medication-related questions or concerns.